What Ubix Therapeutics does

Ubix Therapeutics is a privately held, Seoul-based biopharmaceutical R&D company founded in June 2018 by CEO BK Seo. The company is built around its proprietary Degraducer® platform, a bifunctional small-molecule technology that recruits disease-related target proteins to E3 ubiquitin ligases via a chemical linker, triggering degradation through the Ubiquitin-Proteasome System (UPS). This targeted protein degradation (TPD) modality is positioned to address targets previously considered undruggable by conventional inhibitors and to overcome drug resistance, with primary therapeutic focus on oncology and immuno-oncology.

Its pipeline includes UBX-303-1, an oral BTK degrader that received US FDA clearance in January 2024 to enter a Phase 1 study in relapsed/refractory B-cell malignancies (CLL, DLBCL); UBX-103, an oral androgen receptor (AR) degrader for metastatic castration-resistant prostate cancer that was out-licensed exclusively worldwide to Yuhan in July 2024; and earlier-stage immuno-oncology candidates UBX-106 and UBX-306 (the latter co-developed with NeoImmuneTech). The company is also advancing Degrader-Antibody Conjugates (DAC) through a 2021 co-research agreement with Debiopharm, and is expanding its owned E3 ligase binder library beyond the canonical CRBN/VHL/IAP set. Core enabling capabilities include medicinal chemistry, structural information analysis, in silico CADD, high-throughput screening, and biological assay infrastructure, much of which is sourced or extended through collaborations with Korean research institutes (KRICT, KRIBB, POSTECH, Gachon University, Kyungpook National University).

Because Ubix has no commercialized products, it generates revenue primarily through upfront payments, research funding, and potential milestones from out-licensing and co-development deals with larger pharmaceutical partners. Its customer base is therefore a small set of pharma counterparties (Yuhan, SK Biopharmaceuticals, Debiopharm, NeoImmuneTech), and its go-to-market is licensing-and-collaboration-led rather than direct sales. The company operates 11–50 employees across a headquarters and Bio Research Center in Songpa-gu, Seoul, and a Chemical Research Center in Yeonsu-gu, Incheon.

Name

Ubix Therapeutics

Legal name

(주)Ubix Therapeutics

Website

https://ubixtrx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Ubix Therapeutics is a Seoul-based clinical-stage biopharmaceutical company developing anti-cancer drugs via its proprietary Degraducer® targeted protein degradation platform, out-licensing and co-developing candidates (BTK, AR, immuno-oncology) with larger pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Targeted Protein Degradation Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

Keywords

• Targeted protein degradation
• Anti-cancer therapeutics
• Bifunctional degraders
• Oncology drug development
• E3 ligase binders

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Royalties: The company generates revenue through exclusive licensing agreements where partners receive worldwide rights for preclinical and clinical development and commercialization of drug candidates. Examples include Yuhan licensing UBX-103 (AR degrader) and NeoImmuneTech licensing T-cell suppressor blockade candidates.
2. Co-research Collaboration Revenue: Revenue from research collaboration agreements with pharmaceutical partners such as SK Biopharmaceuticals and Debiopharm, where Ubix provides its Degraducer® platform technology for joint drug development.
3. Technology Transfer: Received technological transfer of novel E3 ligase binder technology from KRICT and KRIBB, which forms the foundation of the Degraducer® platform.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Ubix Therapeutics develops novel anti-cancer and immuno-oncology drug candidates based on its proprietary Degraducer® targeted protein degradation platform. The company creates bifunctional small molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, enabling proteasomal elimination of previously undruggable targets. Its lead asset UBX-303-1 (BTK degrader) received US FDA Phase 1 clearance in January 2024, while UBX-103 (AR degrader) is exclusively licensed to Yuhan, and additional programs (UBX-106, UBX-306, DAC technology) are in research or preclinical stages.

Product overview

Ubix Therapeutics is a biopharmaceutical company developing novel anti-cancer drugs based on its proprietary Degraducer® platform technology. The Degraducer® platform enables targeted protein degradation by creating bifunctional molecules that connect disease-related protein ligands to E3 ubiquitin ligase binders, utilizing the body's Ubiquitin-Proteasome System. The company operates a pipeline of therapeutic programs including UBX-303-1 (BTK degrader for hematological cancers in Phase 1), UBX-103 (AR degrader for prostate cancer licensed to Yuhan), and undisclosed immuno-oncology candidates (UBX-106, UBX-306). Ubix is also advancing novel E3 ligase binder research and Degrader-Antibody Conjugates (DAC) technology in partnership with Debiopharm.

Differentiator

Problem solved

Functional benefit

Products and services

• Degraducer® Platform Technology Bifunctional molecule-based targeted protein degradation technology that connects target protein ligands to E3 ubiquitin ligase binders via linkers, enabling elimination of disease-related proteins that were previously undruggable. Used internally for pipeline development and licensed/co-developed with pharmaceutical partners.
• UBX-303-1 A Bruton's tyrosine kinase (BTK) Degrucer designed to degrade over-expressed BTK proteins through a distinct mechanism of action different from current BTK inhibitors, offering advantages in efficacy, resistance overcoming, and selectivity. Targeted at B-cell malignancies including CLL and DLBCL.
• UBX-103 An oral small molecule androgen receptor (AR) degrader for treatment of metastatic castration resistant prostate cancer, licensed exclusively to Yuhan for worldwide development and commercialization.
• UBX-106 An undisclosed immuno-oncology drug candidate in research stage, part of Ubix's immuno-oncology pipeline.
• UBX-306 An undisclosed immuno-oncology drug candidate developed in collaboration with NeoImmuneTech, in research stage.
• Degrader-Antibody Conjugates (DAC) A novel drug modality combining Degraducer® molecules with antibody drug conjugates, developed in partnership with Debiopharm using their Multilink™ linker technology for targeted cancer therapy.

Quantifiable outcome

• UBX-303-1 showed excellent PK/PD profiles and superior anti-cancer efficacy in C481S mutant Xenograft mouse model and wild-type models
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Ten partnerships are on record, tiered core and flagship.

• Johnson & Johnson Innovation – JLABScoreStrategic or Co-development Partner · 8 October 2024Ubix Therapeutics was accepted into the Johnson & Johnson Innovation – JLABS startup incubator program in October 2024, providing access to mentorship, resources, and networking opportunities within the Johnson & Johnson ecosystem.
• YuhanflagshipOEM/ Whitelabel/ Licensing Partner · 1 July 2024Exclusive license agreement for UBX-103, an oral small molecule AR degrader for treatment of metastatic castration resistant prostate cancer. Yuhan received exclusive worldwide rights for preclinical and clinical development and commercialization.
• SK BiopharmaceuticalscoreStrategic or Co-development Partner · 14 April 2022Research collaboration agreement to develop novel anti-cancer therapeutics using Ubix's Degraducer® platform technology and targeted protein degradation (TPD) combined with SK Biopharmaceuticals' drug development capabilities.
• DebiopharmcoreStrategic or Co-development Partner · 16 June 2021Co-research agreement to develop Antibody Degraducer® Conjugates (ADeC) combining Ubix's Degraducer® molecule with Debiopharm's antibody drug conjugate linker, Multilink™, to specifically target cancer cells.
• NeoImmuneTechcoreOEM/ Whitelabel/ Licensing Partner · 23 March 2020Exclusive License Agreement to develop drug candidates including T-Cell Suppressor Blockades. NeoImmuneTech received rights to advance T-cell related therapeutic candidates.
• KRICT (Korea Research Institute of Chemical Technology)coreTechnology or IntegrationReceived technological transfer of novel E3 ligase binder technology which composes the platform technology Degraducer® from KRICT. Ongoing collaboration to improve and develop Degraducer® applied therapeutics.
• KRIBB (Korea Research Institute of Bioscience and Biotechnology)coreTechnology or IntegrationReceived technological transfer of novel E3 ligase binder technology from KRIBB, forming the foundation of Degraducer® platform. Continuous collaboration to improve and develop Degraducer® applied therapeutics.
• POSTECHcoreTechnology or IntegrationUsing POSTECH's proprietary high-throughput screening (HTS) system to discover groundbreaking ligand hits for previously undruggable target proteins, developing first-in-class drugs through utilization of these hits.
• Gachon UniversitycoreTechnology or IntegrationCollaboration to secure structural information of target proteins, design new drugs based on the data, and discover diverse E3 ligase binders for the Degraducer® platform.
• Kyungpook National UniversitycoreTechnology or IntegrationResearch collaborations based on top-level in-silico screening and in-silico modeling technologies for identifying structural characteristics of drug molecules and proteins and optimizing chemical drug candidates.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Arvinas: Arvinas is the clinical-stage leader in targeted protein degradation using PROTAC bifunctional molecules. Direct competitor in BTK (ARV-102) and AR degrader programs (ARV-110/bavdegalutamide), validating the same therapeutic strategy Ubix pursues with Degraducer®.
• Kymera Therapeutics: Kymera is a clinical-stage TPD biotech with a Pegasus platform using heterobifunctional degraders. Direct competitor in BTK degrader development (KT-0956) and immuno-oncology, employing a similar protein degradation mechanism to Ubix's Degraducer®.
• Nurix Therapeutics: Nurix is a clinical-stage TPD company with both degrader and molecular glue platforms, working on BTK (NX-2127), BCL6, and other oncology targets. Highly comparable business model of platform-based drug discovery with multiple licensing and partnership transactions.
• C4 Therapeutics: C4 Therapeutics develops small molecule degraders using its TORPEDO platform for oncology targets. Direct competitor in bifunctional degrader chemistry with multiple programs in hematological malignancies and solid tumors.
• Monte Rosa Therapeutics: Monte Rosa is a clinical-stage biotech developing molecular glue degraders (MGDs) for cancer and inflammatory diseases. Comparable TPD approach targeting previously undruggable proteins, with clinical-stage assets in oncology.
• Foghorn Therapeutics: Foghorn is a clinical-stage biotech focused on chromatin biology and protein homeostasis, developing degraders for cancer targets. Comparable oncology-focused protein degradation strategy with platform-based discovery approach.

Emerging players

• Amphista Therapeutics: Amphista is an emerging European TPD company developing next-generation bifunctional degraders with novel mechanisms of action. Comparable protein degradation technology but earlier-stage and more limited pipeline than Ubix.

Regional players

• Genexine: Genexine is a Korean clinical-stage biotech developing biologics and immuno-oncology therapeutics. Regional peer where CEO BK Seo previously served as Head of Business Development, providing direct insight into Korean biotech BD practices.

Broad incumbents

• Yuhan Corporation: Yuhan is a major Korean pharmaceutical company that licensed UBX-103 from Ubix for worldwide development. Functions as both partner and broader regional incumbent in Korean pharma with established commercialization infrastructure.
• SK Biopharmaceuticals: SK Biopharmaceuticals is a Korean pharma company with research collaboration agreement with Ubix (2022). Broader pharmaceutical incumbent providing drug development capabilities for Ubix's TPD programs and serving as a regional comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ubix Therapeutics